Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1690-1697.
Prepublished online as a Blood First Edition Paper on May 2, 2006; DOI 10.1182/blood-2005-12-012773.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2005-12-012773v1
108/5/1690    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wunderlich, M.
Right arrow Articles by Mulloy, J. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wunderlich, M.
Right arrow Articles by Mulloy, J. C
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted December 10, 2005
Accepted April 24, 2006

Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability

Mark Wunderlich, Ondrej Krejci, Junping Wei, and James C Mulloy*

Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, OH, USA

* Corresponding author; email: james.mulloy{at}cchmc.org.

The t(16:16) and inv(16) are associated with FAB M4Eo myeloid leukemias and result in fusion of the CBFB gene to the MYH11 gene (encoding SMMHC). Knockout of CBFB causes embryonic lethality due to lack of definitive hematopoiesis. Although knockin of CBFB-MYH11 is not sufficient to cause disease, expression increases the incidence of leukemia when combined with cooperating events. While mouse models are valuable tools in the study of leukemogenesis, little is known about the contribution of CBF{beta}-SMMHC to human hematopoietic stem and progenitor cell self-renewal. We introduced the CBFB-MYH11 cDNA into human CD34+ cells via retroviral transduction. Transduced cells displayed an initial repression of progenitor activity but eventually dominated the culture, resulting in the proliferation of clonal populations for up to 7 months. Long-term cultures displayed a myelomonocytic morphology while retaining multi-lineage progenitor activity and engraftment in NOD/SCID-B2M-/- mice. Progenitor cells from long-term cultures showed altered expression of inv (16)-defining genes identified in microarray studies of human patient samples. This system will be useful in examining the effects of CBF{beta}-SMMHC on gene expression in the human pre-leukemic cell, in characterizing the effect of this oncogene on human stem cell biology and in defining its contribution to the development of leukemia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
O. Krejci, M. Wunderlich, H. Geiger, F.-S. Chou, D. Schleimer, M. Jansen, P. R. Andreassen, and J. C. Mulloy
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death
Blood, February 15, 2008; 111(4): 2190 - 2199.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020